October 7, 2011
Gilead Sciences Inks Licensing Deal for HIV Drug
Kilian Melloy READ TIME: 1 MIN.
Gilead Sciences Inc. said Wednesday that it has obtained the global rights to develop and bring to market an HIV treatment from German pharmaceutical company Boehringer Ingelheim.
The licensing deal calls for Gilead to pay Boehringer an undisclosed upfront payment. Boehringer also could receive additional payments and royalties on future net sales.
The move gives Gilead exclusive, global rights for the research, development and commercialization of Boehringer's non-catalytic site integrase compounds that can inhibit HIV.
Such compounds target the key component of HIV responsible for incorporation of the viral DNA into the human genome.
Gilead Sciences shares ended the regular session up $1.27, or 3.4 percent, at $39.15.
Kilian Melloy serves as EDGE Media Network's Associate Arts Editor and Staff Contributor. His professional memberships include the National Lesbian & Gay Journalists Association, the Boston Online Film Critics Association, The Gay and Lesbian Entertainment Critics Association, and the Boston Theater Critics Association's Elliot Norton Awards Committee.
